Tilbake til søkeresultatene

GAVEFORST-Gaveforsterkningsordningen

Gave fra K.G. Jebsen til NTNU, institutt for sirkulasjon og bildediagnostikk: Senter for hjertetrening 2016-2017

Tildelt: kr 1,0 mill.

The primary long-term objectives are 1) through translational research to determine the health effects of exercise as medicine in prevention and treatment of systolic and diastolic heart failure, and 2) to identify and understand physiological and accelerated ageing and define determinants of development and preservation of good health. • We will determine whether exercise training give more and healthier years through the largest clinical study in elderly people ever that aims to determine whether systematic physical activity actually give more and healthier years. The study will give novel information about how older adults can age successfully. • We aim to optimize the dose-response relationship of exercise intervention in order to prevent (in patients at risk of developing cardiovascular disease) and in treatment of diastolic and systolic heart failure in man. • We will identify cross-sectionally health trends and define its determinants in ˜20,000 adolescents (13-19 yrs) and ˜150,000 adults (20-100 yrs) from different regions in Europe and combine this with longitudinal data in ˜40,000 followed individually for >30 yrs, identifying factors responsible for maintaining health, normal/physiological ageing and disease-free life. Thereby, we will be able to define ´physiological´ vs. ´accelerated´ ageing for different populations (environment, ethnicity, gender, life-style behaviour) in Europe. By applying a system biology approach we will define the next generation of biomarkers for life-style related diseases that are evident long time before clinical manifestation of disease. • We will use a recently established cardiac gene-delivery technique to determine the effect of “candidate genes” as treatment of systolic- and systolic heart failure. This technique is clinically valuable and has the potential to result in cardiac-specific drugs, which do not yet exist.

Budsjettformål:

GAVEFORST-Gaveforsterkningsordningen